Webinar
24 Jan 2023
Container Closure Integrity (CCI) Testing

In this webinar, originally broadcast as part of the Pharmapack Europe show, Robert Schultheis, Founder & Chief Technology Officer, ZebraSci discusses:
Content provided by our supplier
ZebraSci Inc.

-
US
-
2022On CPHI since
-
1Certificates
-
1 - 24Employees
Company types
Primary activities
Other Content from ZebraSci Inc. (2)
-
Brochure Supporting your combination product development from concept to market
Streamlined Solutions. Dependable Service. Technical Expertise. -
Webinar Challenges of Extractables & Leachables Experience
The investigation of the chemical compatibility between a drug product and its container relates to drug product quality, efficacy and safety - critical parameters for the development and commercialisation of a drug product. This implies assessing the extractables and leachables for each new drug product before submission for marketing authorization, and to re-evaluate requirements for each variation of an existing drug product. A 'Toxicological Risk Assessment' must also be conducted to evaluate patient exposure to chemicals over shelf-life and it is the responsibility of a Pharmaceutical company to provide timely evidence on the quality of their finished product. Tools & methodology for E&L studies can be deployed to anticipate challenges and provide key data to de-risk your drug combination product development, even at an early stage.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance